GRAIL, Inc. (GRAL) Stock Price & Analysis

GRAIL, Inc. (GRAL) is trading at USD 159.72, up 1.16% today, as of October 29, 2026 at 17:21 UTC (US market open; quotes may be delayed), according to Nexqual market data.

GRAL last closed at USD 157.88; today's session has ranged USD 155.69–161.9 on volume of 285,252 shares. Market capitalization is $7.13B, with a 52-week range of USD 41.5–166.48 (NMS). Source: Nexqual, retrieved October 29, 2026 at 17:22 UTC.

Also available as compact Markdown for AI agents: nexqual.com/GRAL.md

Key facts (GRAL)

• Last four reported quarters (through Jun 30, 2026): revenue $165M, net income -$392M (-236.9% margin), free cash flow -$296M (SEC filings).
• Insider open-market sales, last ~7 months: 8 Form 4 filings, $14.9M; 3 not under a Rule 10b5-1 plan ($4.7M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.50 on a 1–5 scale) (10 analysts), mean target USD 132.56 (range 74–180).
• Total return with dividends: 1Y +87.4% vs S&P 500 +13.0%; 5Y +992.4% vs S&P 500 +78.9%.
• Next earnings: 2026-11-04, EPS estimate USD -1.9, revenue estimate $44.2M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GRAL)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (GRAL)

P/S 43.2x · P/B 2.8x · FCF yield -4.15% · Earnings yield -5.49%

Insider sales (SEC Form 4, open-market, last ~7 months) (GRAL)

5 of 8 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (GRAL)

Consensus Hold (mean 2.50 on a 1–5 scale), 10 analysts; mean target USD 132.56 (low 74, high 180).

Rating changes, last 120 days:

Total return (dividends reinvested) (GRAL)

GRAL earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

GRAL recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

GRAL revenue by product line (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

GRAL suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 12, 2026.

Companies that name GRAL in their SEC reports

GRAL customer concentration

In the period ended Jun 30, 2026, a single direct customer accounted for 10% of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name it.

GRAL analyst estimates and revisions

GRAL options: expected move

Options price a move of about ±19.3% (±$30.40) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±11.8% on average.

30-day implied volatility 93.2% vs 120.1% realized over the last 30 trading days. Put/call ratio (volume) 0.22. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 17:22 UTC)

Technical Analysis (GRAL)

Nexqual's technical model rates GRAL "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of October 29, 2026 at 17:22 UTC.

Analyst Ratings (GRAL)

Wall Street analysts rate GRAL "Hold" based on 10 analysts, with a mean price target of USD 132.56 (range USD 74–180), per Nexqual as of October 29, 2026 at 17:22 UTC.

Earnings (GRAL)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 17:22 UTC.

Financials & Fundamentals (GRAL)

Source: Nexqual, October 29, 2026 at 17:22 UTC.

Financial Health Score (GRAL)

Nexqual rates GRAIL, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 17:22 UTC.

Ownership (GRAL)

Source: Nexqual, October 29, 2026 at 17:22 UTC.

Leadership (GRAL)

GRAIL, Inc. is led by Joshua J. Ofman M.D., M.S.H.S, CEO & Director, per Nexqual as of October 29, 2026 at 17:22 UTC.

Major Backers & Investors (GRAL)

Notable institutional backers of GRAIL, Inc. include Farallon Capital Management LLC, Baker Bros. Advisors, LP, Primecap Management Company, according to Nexqual as of October 29, 2026 at 17:22 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 17:22 UTC.

From GRAIL, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• The law included certain standards, including that Centers for Medicare and Medicaid Services ("CMS") would establish coverage through a national coverage determination ("NCD") process under "reasonable and necessary" evidentiary requirements.
• We can leverage our proprietary platform for additional applications, including our precision oncology portfolio.
• The commercial opportunity for Galleri is significant, with more than 300 million individuals globally over the age of 50 (our intended use population), including more than 100 million individuals in the United States.
• Our proprietary targeted methylation platform, as well as our growing body of clinical and real-world data, have provided us with unique insights into cancer biology that enable development of products beyond asymptomatic screening.

Partnerships

• We have also begun entering select international markets through distributor partners, including Israel and Canada, and intend to enter South Korea through our partnership with Samsung.
• Under our agreement with the NHS, these results have met certain success criteria and missed others.

Legal & Regulatory Risks (Item 1A, quoted)

• The PMA approval process can be expensive, lengthy and uncertain.
• The global data protection landscape is rapidly evolving and we and our partners are or may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address data privacy and security).
• We receive, store, process and disclose personal information as part of our business and as our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities.
• Our business may be affected by the evolving regulatory framework for AI Technologies.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 17:22 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt